Ovarian Cancer

Ovarian cancer is one of the strongest translational settings for WFA.

It combines robust preclinical synergy data, direct cancer stem cell relevance, and an active human trial landscape.

Why ovarian cancer is such a good fit

A central problem in ovarian cancer is persistence of stem-like, treatment-resistant cell populations after chemotherapy. WFA repeatedly looks relevant in exactly that space.

It does not just add generic cytotoxicity. It appears to correct part of the stem-cell enrichment problem that platinum therapy can worsen.

Cell data

WFA alone and in combination with cisplatin has reduced CSC-enriched populations marked by CD44, CD24, CD34, CD117, and Oct4 in ovarian models.

It also suppresses Notch1/Hes1/Hey1 signalling, which is closely tied to CSC self-renewal. That matters because cisplatin can move this pathway in the opposite direction.

This makes the combination mechanistically attractive rather than simply additive.

Animal data

In orthotopic ovarian tumour models, WFA plus cisplatin produced major tumour-growth reduction and strong suppression of metastasis. Work in ALDH1+ CSC-enriched tumours also showed inhibition of spheroid formation.

A separate line of work suggests WFA may help address ovarian cancer-associated cachexia, including skeletal muscle wasting. That is an unusual additional angle and may matter clinically if it translates.

Human data

The most advanced current human study is an ovarian cancer trial combining Ashwagandha extract with liposomal doxorubicin.

That is an important translational step, but it still does not provide purified-WFA efficacy data.

Clinical setting assessment

Ovarian cancer is likely the most clinically advanced WFA setting right now.

The reason is not only the active trial. It is also the underlying biology. CSC depletion, platinum resistance relevance, and metastasis control all fit the disease well.

Bottom line

Ovarian cancer is one of the strongest near-term areas to watch for clinically meaningful WFA translation.

Key references

Kakar S. et al. — ovarian-cancer cisplatin synergy and cancer stem cell depletion in vivo.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4218168/

Mukherjee A. et al. — ovarian-cancer cachexia and muscle-wasting relevance.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12487364/

University of Louisville recurrent ovarian cancer trial listing.
https://ctv.veeva.com/study/combination-therapy-for-recurrent-ovarian-cancer

Access and availability:
Source: MCS Formulas, “Withaferin A Pro Liposomal.”
50 mg WFA per capsule. Available via healthcare professional request.
https://www.mcsformulas.com/vitamins-supplements/withaferin-a-pro-liposomal/ref/14